Tenax Therapeutics (TENX) Asset Writedowns and Impairment (2011 - 2016)

Tenax Therapeutics' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $33.3 million for Q4 2016.

• In Q4 2016, Asset Writedowns and Impairment changed N/A year-over-year to $33.3 million; the TTM figure through Dec 2016 stood at $33.3 million (changed N/A YoY), while the FY2016 annual figure was $33.3 million, up 3114.44% from the prior year.
• Asset Writedowns and Impairment came in at $33.3 million for Q4 2016 at Tenax Therapeutics, up from $24110.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $33.3 million in Q4 2016 to a low of $24110.0 in Q2 2013.
• A 3-year average of $8.4 million and a median of $60423.5 in 2012 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment plunged 90.81% in 2012 and dropped 13.14% in 2013, its largest moves.
• Tenax Therapeutics' Asset Writedowns and Impairment stood at $27758.0 in 2012, then dropped by 13.14% to $24110.0 in 2013, then jumped by 137872.21% to $33.3 million in 2016.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $33.3 million, $24110.0, and $27758.0 for Q4 2016, Q2 2013, and Q2 2012 respectively.

Peer Comparison